P11.23 Oncolytic adenovirus Delta-24-RGD exerts a potent anti-tumor effect in preclinical models of atypical teratoid/rhabdoid tumors

Por Garcia Moure, M, González Huarriz, M, Marrodán, L, Patiño-García, A, Alonso, M M
Publicado no Neuro Oncol (2019)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients

Por Abajo, A, Boni, V, Lopez, I, Gonzalez-Huarriz, M, Bitarte, N, Rodriguez, J, Zarate, R, Bandres, E, Garcia-Foncillas, J
Publicado em 2012

P11.56 Oncolytic virus and tumor microenvironment modulators an alliance to fight glioblastoma

Por Puigdelloses, M, Martinez-Velez, N, García-Moure, M, Gonzalez-Huarriz, M, Iñigo, I, Marta, A M, Gallego Perez-Larraya, J
Publicado no Neuro Oncol (2019)

OS5.1 Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs

Por Alonso, M M, Iñigo, I, Gonzalez-Huarriz, M, Dominguez, P, Patiño, A, Jones, C, Gomez-Manzano, C, Fueyo, J, Díez-Valle, R, Tejada, S
Publicado no Neuro Oncol (2019)

OS1.1 Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL

Por Puigdelloses, M, González-Huarriz, M, Zandio, B, Besora, S, Bruna, J, Petrirena, G, Marigil, M, Díez-Valle, R, Tejada, S, Nuñez, J, Alonso, M, Gállego Pérez-Larraya, J
Publicado no Neuro Oncol (2018)